Are tumoral factors responsible for host tissue wasting in cancer cachexia?

Future Oncology

Volumn 6, Issue 4, 2010, Pages 503-513

  Tisdale, Michael J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Cytokine; Proteolysisinducing factor; Zinc 2 glycoprotein

Indexed keywords

ALPHA2 GLYCOPROTEIN; APPETITE STIMULANT; FATTY ACID; GAMMA INTERFERON; GLYCEROL; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE SENSITIVE LIPASE; ICOSAPENTAENOIC ACID; INFLIXIMAB; INITIATION FACTOR 2ALPHA; INTERLEUKIN 1; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; LIPID MOBILIZER HORMONE; MELANOCORTIN RECEPTOR; MESSENGER RNA; PENTOXIFYLLINE; PROTEOLYSIS INDUCING FACTOR; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN;

ADIPOCYTE; ANOREXIA; CACHEXIA; CANCER PATIENT; CELL DIFFERENTIATION; DEPLETION; DIET SUPPLEMENTATION; FOOD INTAKE; HUMAN; LIPID HYDROLYSIS; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROSCOPY; MUSCLE ATROPHY; NEOPLASM; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; WESTERN BLOTTING; WHITE ADIPOSE TISSUE;

CACHEXIA; CYTOKINES; HUMANS; NEOPLASMS; TUMOR NECROSIS FACTORS;

EID: 77950605203     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.20     Document Type: Review

References (97)

1. Teunissen SC, Wesker W, Kruilwagen C et al.: Symptom prevalence in patients with incurable cancer: a systematic review. J. Pain Symptom Manage. 34, 94-104 (2007).
2. Tan BHL, Fearon KCH: Cachexia: prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care 11, 400-407 (2008).
3. DeWys WD, Begg C, Lavin PT et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med. 69, 491-497 (1980).
4. Marinoho LA, Rettori O, Vieira-Matos AN: Body weight loss as an indicator of breast cancer recurrence. Acta Oncologica 40, 832-837 (2001).
5. Cohn SA, Gartenhaus W, Sawitsky A et al.: Compartmental body composition of cancer patients with measurement of total body nitrogen, potassium and water. Metabolism 30, 222-229 (1981).
6. Fearon KCH: The mechanisms and treatment of weight loss in cancer. Proc. Nutr. Soc. 51, 251-265 (1992).
7. Heymsfield SB, McManus CB: Tissue components of weight loss in cancer patients. Cancer 55, 2238-2242 (1985).
8. Evans WK, Makuch R, Clamon GH et al.: Limited impact of total parenteral nutrition on nutrition status during treatment for small cell lung cancer. Cancer Res. 45, 3347-3352 (1985).
9. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD: Body composition changes in patients who gain weight while receiving megestrol acetate. J. Clin. Oncol. 11, 152-154 (1993).
10. Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF: Effects of medroxyprogesterone acetate on food intake, body composition and resting energy expenditure in patients with advanced, non-hormone-sensitive cancer. Cancer 82, 553-560 (1998).
11. Bosneus I, Daneryd P, Svanberg E, Lundholm K: Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int. J. Cancer 93, 380-383 (2001).
12. Bing C, Brown M, King P, Collins P, Tisdale MJ, Williams G: Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res. 60, 2405-2410 (2000).
13. Fan W, Boston BA, Keterson RA, Hruby VJ, Cone RD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 365, 165-168 (1997). (Pubitemid 27034218)
14. Wisse BE, Frayo RS, Schwartz MW, Cumings DE: Reversal of cancer anorexia by blockage of central melanocortin receptors in rats. Endocrinology 14, 3292-3301 (2001).
15. Marks DL, Ling N, Cone RD: Role of central melanocortin system in cachexia. Cancer Res. 61, 1432-1438 (2001).
16. Billingsley KG, Fraker DL, Strassman G, Loeser C, Fliot HM, Alexander HR: Macrophage-derived tumor necrosis factor and tumor-derived leukaemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann. Surg. Oncol. 3, 29-35 (1996).
17. Bing C, Bao U, Jenkins J et al.: Zinc-a2- glycoprotein, a lipid mobilising factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc. Natl Acad. Sci. USA 101, 2500-2505 (2004).
18. Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ: Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br. J. Cancer 76, 606-613 (1997).
19. Tisdale MJ: Mechanism of cancer cachexia. Physiol. Rev. 89, 381-1340 (2009).
20. Bing C, Russell S, Becket E et al.: Adipose atrophy in cancer cachexia morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br. J. Cancer 95, 1028-1037 (2006).
21. Agustsson T, Ryden M, Hoffstedt J et al.: Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 67, 5531-5537 (2007).
22. Ryden M, Agustsson T, Laurencikiene J et al.: Lipolysis - not inflammation, cell death, or lipogenesis - is involved in adipose tissue loss in cancer cachexia. Cancer 113, 1695-1704 (2008).
23. Drott C, Persson H, Lundholm K: Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. Clin. Physiol. 9, 427-439 (1989).
24. Shaw JH, Wolfe RR: Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann. Surg. 205, 368-376 (1987).
25. Islam-Ali B, Khan S, Price SA, Tisdale MJ: Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilising factor (LMF). Br. J. Cancer 85, 758-763 (2001).
26. Thompson MP, Cooper ST, Parry BR, Tuckey JA: Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients. Biochim. Biophys. Acta 1180, 236-242 (1993).
27. Laurencikiene J, Stenson BM, Nordström EA et al.: Evidence for an important role of CIDEA in human cancer cachexia. Cancer Res. 68, 9247-9254 (2008).
28. Lundholm K, Daneryd P, Körner U, Hyltander A, Bosaeus I: Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int. J. Oncol. 24, 505-512 (2004).
29. Virtanen KA, Lidell ME, Orava J et al.: Functional brown adipose tissue in healthy adults. N. Eng. J. Med. 360, 1518-1525 (2009).
30. Shellock FG, Riedinger MS, Fishbein MC: Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J. Cancer Res. Clin. Oncol. 111, 82-85 (1986).
31. Collins P, Bing C, McCulloch P, Williams G: Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. Br. J. Cancer 86, 372-375 (2002).
32. Beutler B, Cermai A: Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320, 584-588 (1986).
33. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ: Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res. 58, 2359-2365 (1998).
34. Zhang HH, Halbleib M, Ahmad F, Manganiello VC, Greenberg AS: Tumor necrosis factor-a stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51, 2929-2935 (2002).
35. Bing C, Russell ST, Beckett EE et al.: Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilising factor. Br. J. Cancer 86, 612-618 (2002).
36. Busquets S, Sanchis D, Alvarez B, Ricquier D, Lopez-Soriano FJ, Argiles JM: In the rat, tumor necrosis factor a administration results in an increase in both UCP2 and UCP3 mRNA in skeletal muscle: a possible mechanism for cytokine-mediated thermogenesis? FEBS Lett. 440, 348-350 (1998).
37. Sanders PM, Tisdale MJ: Effect of zinc-a2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett. 212, 71-81 (2004).
38. Russell ST, Hirai K, Tisdale MJ: Role of b3-adrenergic receptors in the action of a tumor lipid mobilising factor. Br. J. Cancer 86, 424-428 (2002).
39. Hyltander A, Daneryd P, Sandstrom R et al.: b-adrenoreceptor activity and resting energy metabolism in weight losing cancer patients. Eur. J. Cancer 36, 330-334 (2000).
40. Mracek T, Ding Q, Tzanavati T et al.: The adipokine zinc-a2-glycoprotein is down regulated with fat mass expansion in obesity. Clin Endocrinol. DOI: 10.111/j.1365-2265.2009.0.3658.x (2010) (Epub ahead of print).
41. Rolli V, Radosavljevic M, Astier V et al.: Lipolysis is altered in MHC class I zinc-a2-glycoprotein deficient mice. FEBS Lett. 581, 394-400 (2007).
42. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P: Zinc-a2- glycoprotein, a lipid mobilising factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett. 579, 41-47 (2005).
43. Khal J, Hine AV, Fearon KCH, Dejong CHC, Tisdale MJ: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. 37, 2196-2206 (2005). (Pubitemid 41206831)
44. Eley HL, Skipworth RJE, Deans DAC, Fearon KCH, Tisdale MJ: Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2a may signal skeletal muscle atrophy in weight-losing cancer patients. Br. J. Cancer 98, 442-449 (2008).
45. Emery PW, Edwards RHT, Rennie MJ, Souhami RL, Halliday D: Protein synthesis in muscle measured in vivo in cachectic patients with cancer. Br. Med. J. 289, 584-588 (1984).
46. Eley HL, Tisdale MJ: Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282, 7087-7097 (2007).
47. Llovera M, Lopez-Soriano FJ, Argiles JM: Effects of tumor necrosis factor-a on muscle protein turnover in female Wistar rats. J. Natl Cancer Inst. 85, 1334-1339 (1993). (Pubitemid 23249726)
48. Tsujinaka T, Fujita J, Ebisui C et al.: Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J. Clin. Invest. 97, 244-249 (1996). (Pubitemid 26022595)
49. Llovera M, Carbo N, Lopez-Soriano FJ et al.: Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 13, 83-87 (1998). (Pubitemid 29069115)
50. Batgalvis KA, Berger FG, Pena MMD, Davis JM, Muga SJ, Carson JA: Interleukin-6 and cachexia in ApcMin/+mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R393-R401 (2008).
51. Garcia Martinez C, Llovera M, Agell N et al.: Ubiquitin gene expression in skeletal muscle is increased during sepsis. Involvement of TNF-a but not IL-1. Biochem. Biophys. Res. Commun. 217, 839-844 (1995). (Pubitemid 26019732)
52. Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ: Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myotubes in vitro by a proteolysis-inducing factor (PIF). Br. J. Cancer 85, 297-302 (2001). (Pubitemid 32695755)
53. Li Y-P, Chen Y, John J et al.: TNF-a acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin 1/MAFbx in skeletal muscle. FASEB J. 19, 362-370 (2005). (Pubitemid 40316524)
54. Li Y-P, Schwartz RJ, Waddell ID, Holloway BR, Reid MB: Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kB activation in response to tumor necrosis factor a. FASEB J. 12, 871-880 (1998). (Pubitemid 28294677)
55. Russell ST, Eley H, Tisdale MJ: Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell. Sig. 19, 1797 - 1806 (2007). (Pubitemid 46935435)
56. Eley HL, Russell ST, Tisdale MJ: Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by b-hydroxy-b-methylbutyrate. Am. J. Physiol. Endocrinol. Metab. 295, E1409-E1416 (2008).
57. Schwarzkopf M, Coletti D, Sassoon D, Marazzi G: Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. Genes Develop. 20, 3440-3452 (2006). (Pubitemid 44969161)
58. Gutteridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr: NF-kB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289, 2363-2366 (2000).
59. Ling PR, Schwartz JH, Bistrian BR: Mechanisms of host wasting induced by administration of cytokines in rats. Am. J. Physiol. Endocrinol. Metab. 272, E333-E339 (1997). (Pubitemid 27148734)
60. Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ: Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br. J. Cancer 78, 850-856 (1998). (Pubitemid 28430012)
61. Lorite MJ, Cariuk P, Tisdale MJ: Induction of muscle protein degradation by a tumour factor. Br. J. Cancer 76, 1035-1040 (1997). (Pubitemid 27434660)
62. Llovera M, Lopez-Soriano FJ, Argiles JM: Effects of tumor necrosis factor-a on muscle protein-turnover in female Wistar rats. J. Natl Cancer Inst. 85, 1334-1339 (1993). (Pubitemid 23249726)
63. Norton JA, Morley JF, Green MV et al.: Parabiotic transfer of cancer anorexia/cachexia in male rats. Cancer Res. 45, 5547-5552 (1985).
64. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M: Characterization of a cancer cachectic factor. Nature 379, 739-742 (1996). (Pubitemid 26061738)
65. Todorov PT, Field WN, Tisdale MJ: Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br. J. Cancer 80, 1734-1737 (1990).
66. Monitto CL, Dong S-M, Jen J, Sidransky D: Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin. Cancer Res. 10, 5862-5869 (2004).
67. Todorov PT, Deacon M, Tisdale MJ: Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J. Biol. Chem. 272, 12279-12288 (1997).
68. Schittek B, Hipfel R, Sauer B et al.: Dermicidin: a novel human antibiotic peptide secreted by sweat glands. Immunol. Nat. 2, 1133-1137 (2001).
69. Wang Z, Corey E, Hass GM et al.: Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int. J. Cancer 105, 123-129 (2003).
70. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KCH: Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br. J. Surg. 87, 53-58 (2000).
71. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P, Wainer IW: Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br. J. Cancer 84, 1599-1601 (2001).
72. Williams ML, Torres-Duarte A, Brant LJ, Bhargava P, Marshall J, Wainer IW: The relationship between a urinary cachectic factor and weight loss in advanced cancer patients. Cancer Invest. 22, 866-870 (2004).
73. Wieland BM, Stewart GD, Skipworth RJE et al.: Is there a human homologue to the murine proteolysis-inducing factor? Clin. Cancer Res. 13, 4984-4992 (2007).
74. Kamoshida S, Watanabe, Suzuki M et al.: Expression of cancer cachexia-related factors in human cancer xenografts: an immunohistochemical analysis. Biomed. Res. 27, 275-281 (2006).
75. Karayiannakis AJ, Syrigos KN, Polychronidis A et al.: Serum levels of tumor necrosis factor-a and nutritional status in pancreatic cancer patients. Anticancer Res. 21, 1355-1358 (2001).
76. Bossola M, Muscaritoli M, Bellantone R et al.: Serum tumor necrosis factor-a levels in cancer patients correlate with weight loss. Eur. J. Clin. Invest. 30, 1107-1112 (2000).
77. Ebrahimi B, Tuker SL, Li D et al.: Cytokines in pancreatic carcinoma. Cancer 101, 2727-2736 (2004).
78. Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A: Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J. Natl Cancer Inst. 50, 595-598 (1998).
79. Maltoni M, Fabbri L, Nanni O et al.: Serum levels of tumour necrosis factor and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support. Care Cancer 5, 130-135 (1997).
80. Adami F, Guarini A, Pini M et al.: Serum levels of tumour necrosis factor-a in patients with B-cell chronic lymphocytic leukaemia. Eur. J. Cancer 30A, 1259-1263 (1994).
81. McKeowa DJ, Brown DFJ, Kelly A et al.: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with nonsmall cell lung cancer. Br. J. Cancer 91, 1993-1995 (2004).
82. Costelli P, Bossola M, Muscaritoli M et al.: Anticytokine treatment prevents the increase in the activity of the ATP-ubiquitin-and Ca2+-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine 19, 1-5 (2002).
83. Goldberg RM, Loprinzi CL, Malliard JA et al.: Pentoxyifylline for treatment of cancer anorexia and cachexia? A randomised, double-blind, placebo-controlled trial. J. Clin. Oncol. 13, 2856-2859 (1995).
84. Costelli P, Carbo N, Tessitore L et al.: Tumor necrosis factor-a mediates changes in tissue protein turnover in a rat cancer cachexia model. J. Clin. Invest. 92, 2783-2789 (1993).
85. Widenmann B, Malfertheiner P, Freiss H et al.: A multicenter Phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J. Support. Oncol. 6, 18-25 (2008).
86. Wyke SM, Russell ST, Tisdale MJ: Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kB activation. Br. J. Cancer 91, 1742-1750 (2004).
87. Eley HL, Russell ST, Tisdale MJ: Attenuation of muscle atrophy in a murine model of cachexia by inhibition of the dsRNA-dependent protein kinase. Br. J. Cancer 96, 1216-1222 (2007).
88. Eley HL, Russell ST, Tisdale MJ: Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem. J. 407, 113-120 (2007).
89. Russell ST, Siren PMA, Siren MJ, Tisdale MJ: Attenuation of skeletal muscle atrophy in cancer cachexia by d-myo-inositol 1, 2 6-triphosphate. Cancer Chemother. Pharmacol. 64, 517-527 (2009).
90. Smith HJ, Mukerji P, Tisdale MJ: Attenuation of proteasome-induced proteolysis in skeletal muscle by b-hydroxy-b-methylbutyrate in cancer-induced muscle loss. Cancer Res. 65, 277-283 (2005).
91. Beck SA, Smith KL, Tisdale MJ: Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 51, 6089-6093 (1991).
92. Todorov PT, Wyke SM, Tisdale MJ: Identification and characterisation of a membrance receptor for proteolysis-inducing factor in skeletal muscle. Cancer Res. 67, 11419-11427 (2007).
93. Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KCH: Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr. Cancer 36, 177-184 (2000).
94. Fearon KCH, van Meyenfeldt MF, Moses AGW et al.: Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52, 1479-1486 (2003).
95. May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN: Reversal of cancer-related wasting using oral supplementation with a combination of b-hydroxy-b-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183, 471-479 (2002).
96. Deans DAC, Tan BHL, Ross JA et al.: Cancer cachexia is associated with the IL10-1082 gene promoter polymorphism in patients with gastroesophageal malignancy. Am. J. Clin. Nutr. 89, 1164-1172 (2009).
97. Lainscak M, Podbregar M, Anker SD: How does cachexia influence survival in cancer, heart failure and other chronic diseases? Curr. Opin. Support. Pall. Care 1, 299-305 (2007).